Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected ...

From about $63 on Aug. 18, the stock more than doubled the next day and has since climbed further. August ended at $140.34; September's advance has added roughly another 39% into Thursday's session, ...

Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with ...

Moderna (MRNA) reached a 52-week high as CEO Bancel emphasized the company's mRNA platform capabilities beyond COVID vaccines, spotlighting cancer treatment.

Dispositivos para automatizar tarefas podem trazer mais praticidade e controle para diferentes ambientes da casa ...

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rallying again as investors position ahead of a late-October data drop that could validate the first personalized cancer therapy tested at ...

Moderna (MRNA) stock hit a 52-week high after CEO Bancel said the company is an mRNA platform, not just a Covid vaccine maker ...

Una metropoli moderna che unisce grattacieli futuristici a capolavori culturali, ideale da esplorare a piedi per cogliere i contrasti tra tradizione ...

In the latest session on Tuesday, 22 September 2026, Moderna opened at USD 168.58. During the day, the shares reached a high ...

瑞银在Moderna关键黑色素瘤三期试验数据公布前，维持对该股的“中性”评级，目标价150美元。 市场目前高度关注Moderna辅助治疗黑色素瘤研究的三期结果。相关数据将以最新摘要形式在欧洲肿瘤内科学会会议上公布，核心指标是无复发生存期。 在瑞银看来 ...

Saranno 160 gli espositori complessivi, provenienti dal Friuli Venezia Giulia, da altre regioni italiane e dalla Slovenia, ...